Assembly Biosciences (NASDAQ:ASMB) Chief Medical Officer Anuj Gaggar outlined the company’s virology strategy and upcoming clinical priorities during a Bank of America-hosted discussion, emphasizing programs in herpes simplex virus, hepatitis D and transplant-related herpes viruses.
Gaggar described Assembly as a clinical-stage research and development company focused on serious viral illnesses where patients still lack adequate treatment options. He said the company has a broad partnership with Gilead Sciences and has advanced four new molecules into the clinic over the past two and a half years, generating what he characterized as positive data across those programs.
